A Phase II Study of JNJ-68284528 CAR T-Cell Therapy to Treat Multiple Myeloma


Full Title

A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma (CARTITUDE-2)


CAR T-cell therapy is a type of immunotherapy. During CAR T-cell therapy, a patient’s own T cells (a type of white blood cell) are removed and genetically modified in the laboratory to recognize a protein on their cancer cells. The modified T cells are multiplied in the lab and returned to the patient to find and destroy cancer cells. 

In this study, researchers are evaluating the effectiveness of a CAR T-cell therapy called JNJ-68284528 (Cilta-cel) in patients with multiple myeloma that has come back or continued to grow despite initial treatment. JNJ-68284528 recognizes a protein on most multiple myeloma cells called BCMA. Patients whose multiple myeloma remains after autologous stem cell transplantation will receive lenalidomide in addition to JNJ-68284528.

Who Can Join

To be eligible for this study, patients must meet several criteria (which vary depending on their treatment history), including but not limited to the following:

  • Patients must have multiple myeloma that came back or persists despite prior treatment.
  • Patients should recover from the serious side effects of previous therapies before receiving the study treatment.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.



For more information and to ask about eligibility for this study, please contact the office of Dr. Alexander Lesokhin at 646-608-3717.




Phase II (phase 2)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID